Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5279675 | 0.84 | GAA (0.60) | POLBGAANPSR1SMN1; SMN2KDM4E | |
| SCHEMBL13279565 | 0.83 | MEN1 (0.63) | POLBCYP1A2CYP2C19SMN1; SMN2MAPT | |
| SCHEMBL11815554 | 0.83 | GAA (0.72) | POLBGAANPSR1SMN1; SMN2KDM4E | |
| SCHEMBL4169834 | 0.81 | NPSR1 (0.66) | POLBGAANPSR1SMN1; SMN2KDM4E | |
| SCHEMBL5202817 | 0.81 | GAA (0.66) | POLBGAANPSR1CYP1A2SMN1; SMN2 | |
| SCHEMBL12953204 | 0.81 | POLB (0.50) | POLBGAANPSR1CYP1A2CYP2C19 | |
| SCHEMBL9267668 | 0.81 | GAA (0.70) | POLBGAANPSR1SMN1; SMN2KDM4E | |
| SCHEMBL1107148 | 0.81 | GAA (0.70) | POLBGAANPSR1SMN1; SMN2KDM4E | |
| SCHEMBL11550281 | 0.81 | GAA (0.70) | POLBGAANPSR1SMN1; SMN2KDM4E | |
| SCHEMBL2173764 | 0.81 | PSEN1 (0.52) | POLBGAACYP1A2CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100406013-C | Camptothecin derivatives | CALIFORNIA PACIFIC MED CENTER (US) | 2008-07-30 | — | — | CN | disclosed |
| US-RE39707-E1 | Camptothecin derivatives | CATHOLIC HEALTHCARE WEST (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1353673-B1 | CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MED CENTER (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2005123714-A1 | QUINAZOLINE COMPOUNDS AND THEIR USE IN MCH-RELATED DISEASE | 7TM PHARMA A/S (DK) | 2005-12-29 | — | — | WO | disclosed |
| CN-1553802-A | Camptothecin derivatives | ����������̫ƽ��ҽѧ���� | 2004-12-08 | — | — | CN | disclosed |
| US-20040034050-A1 | Homo-camptothecin derivatives | CATHOLIC HEALTHCARE WEST, DOING BUSINESS AS ST. MARY'S MEDICAL CENTER OF SAN FRANCISCO | 2004-02-19 | — | — | US | disclosed |
| WO-2003101406-A1 | HOMO-CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2003-12-11 | — | — | WO | disclosed |
| EP-1353673-A1 | CAMPTOTHECIN DERIVATIVES | California Pacific Medical Center (US) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002056885-A1 | CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2002-07-25 | — | — | WO | disclosed |
| US-6350756-B1 | USEFUL FOR TREATING CANCER; (20S) ESTERS WITH AN OXYALKANOIC ACID; | CALIFORNIA PACIFIC MEDICAL CENTER | 2002-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034050-A1 | Homo-camptothecin derivatives | CYP8B1, HCAR3, MTHFD2 | POLB 2416/4885GAA 3986/4885NPSR1 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.